AAN releases Evidence in Focus Article on new gene therapy for Duchenne muscular dystrophy

AAN releases Evidence in Focus Article on new gene therapy for Duchenne muscular dystrophy

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article, published May 14, 2025, online in Neurology.

Duchenne muscular dystrophy gene therapy

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

High hopes and high costs: Exploring advances in Duchenne muscular dystrophy gene therapy

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article in Neurology.

A little boy needs gene therapy because he suffers from Duchenne syndrome.

'Making the most of every day' Armidale family runs for hope in Duchenne awareness

Armidale family embarks on City to Surf to battle Duchenne Muscular Dystrophy and raise over $5,000 to aid in DMD awareness and research.

The genetic, hereditary disease occurs almost exclusively in boys, at an early age, and in Serbia, it affects between 200 and 250 children.